Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
Status:
Recruiting
Trial end date:
2024-12-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to better understand how the immune system plays a role in
fighting breast cancer and specifically research if the immune system response against breast
cancer can be improved with endocrine therapy and cyclin dependent kinase inhibitor therapy
in patients with hormone receptor positive breast cancer. This will be studied by collecting
tumor tissue and blood samples before and after 2 weeks of study treatment with commonly used
endocrine therapy and cyclin dependent kinase inhibitor therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Cancer Prevention Research Institute of Texas Eli Lilly and Company